Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572974 | 1.00 | CYP1A2 (0.69) | CYP1A2CYP2D6KCNH2HRH1ABCB1 | |
| Ammonia Solution, Strong SCHEMBL21752109 | 0.98 | CYP1A2 (0.67) | CYP1A2CYP2D6KCNH2HRH1ABCB1 | |
| Hydrochloric Acid SCHEMBL10981614 | 0.98 | CYP1A2 (0.67) | CYP1A2CYP2D6KCNH2HRH1ABCB1 | |
| Bromide SCHEMBL7912525 | 0.98 | CYP1A2 (0.67) | CYP1A2CYP2D6KCNH2HRH1ABCB1 | |
| Bromide SCHEMBL6565773 | 0.98 | CYP1A2 (0.67) | CYP1A2CYP2D6KCNH2HRH1ABCB1 | |
| SCHEMBL230753 | 0.88 | HRH1 (0.73) | CYP1A2CYP2D6HRH1HRH3ALOX15 | |
| SCHEMBL29485678 | 0.88 | HRH1 (0.73) | CYP1A2CYP2D6HRH1HRH3ALOX15 | |
| SCHEMBL2750398 | 0.87 | CYP1A2 (0.65) | CYP1A2CYP2D6KCNH2HRH1ABCB1 | |
| SCHEMBL29362356 | 0.87 | HRH1 (0.58) | CYP1A2CYP2D6HRH1ABCB1HTR1A | |
| SCHEMBL6423073 | 0.87 | HRH1 (0.63) | CYP1A2CYP2D6HRH1ABCB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | claimed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2017034377-A1 | PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A ST CO., LTD. (KR) | 2017-03-02 | — | — | WO | claimed |
| US-20150303390-A1 | SEQUENCE DEPENDENT ASSEMBLY TO CONTROL MOLECULAR INTERFACE PROPERTIES FOR MEMORY DEVICES, SOLAR CELLS AND MOLECULAR DIODES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-10-22 | — | — | US | claimed |
| EP-2909871-A2 | SEQUENCE DEPENDENT ASSEMBLY TO CONTROL MOLECULAR INTERFACE PROPERTIES FOR MEMORY DEVICES, SOLAR CELLS AND MOLECULAR DIODES | Yeda Research and Development Co. Ltd (IL) | 2015-08-26 | — | — | EP | claimed |
| CN-104672311-A | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH INC | 2015-06-03 | — | — | CN | claimed |
| WO-2014061018-A2 | SEQUENCE DEPENDENT ASSEMBLY TO CONTROL MOLECULAR INTERFACE PROPERTIES FOR MEMORY DEVICES, SOLAR CELLS AND MOLECULAR DIODES | YEDA RESEARCH AND DEVELOPMENT CO. LTD AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2014-04-24 | — | — | WO | claimed |
| CN-103124726-A | Pyrazole amide compound and use thereof | SINOCHEM CORP | 2013-05-29 | — | — | CN | claimed |
| CN-1531541-A | Rhodium and iridium complexes | �����л��뵼������˾ | 2004-09-22 | — | — | CN | claimed |
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | BRILLIANT LIGHT POWER, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023216122-A1 | SINGLET OXYGEN TYPE PHOTOSENSITIZING MATERIAL HAVING AGGREGATION-INDUCED EMISSION PERFORMANCE, AND PREPARATION METHOD AND USE THEREFOR | 华南理工大学 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-1999055322-A1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| EP-0770065-A1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995035281-A1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
| US-4873335-A | 3-phenethyl-2-benzene-amides or aza-derivatives thereof | SCHERING CORPORATION (US) | 1989-10-10 | — | — | US | disclosed |
| US-4731447-A | Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof | SCHERING CORPORATION (US) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | SCO2, SOD1, HAO2 | CYP1A2 1592/4885CYP2D6 4019/4885KCNH2 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.